UK Medicine Export Restrictions 2026: What Overseas Buyers Need to Know

Every UK-licensed medicine that leaves a wholesaler's warehouse for an overseas buyer has, in principle, cleared one more check than most buyers ever see: is this specific product currently free to export. For the great majority of medicines the answer is straightforwardly yes. For a defined and changing subset, the answer is no, or not without prior authorisation, because the UK government has restricted its export to protect supply for UK patients.

This matters to overseas buyers for a very practical reason. If a UK supplier you have bought a line from for years suddenly cannot quote it, the reflex is to assume something has gone wrong with the relationship, or to look for someone else who will simply say yes. Neither reaction is right if the real cause is a UK export restriction. Understanding how the mechanism works, and how a properly licensed wholesaler is required to respond to it, changes how you read that refusal and how you plan around it.

This guide sets out the mechanism in plain terms: why it exists, who enforces it, what has historically been affected, and what a buyer should do when it bites. It is written from the perspective of a UK MHRA-licensed wholesale exporter that has to check this position before every quote, not as legal advice, and not as a definitive product list. The list itself changes, sometimes with very little notice, and the only reliable way to know a specific product's current status is to check at the point of enquiry.

Why the UK Restricts Export of Certain Medicines

UK wholesalers are, as a matter of routine business, free to export licensed medicines. The trade that Euro Biom and comparable licensed exporters conduct with hospitals, Ministries of Health, NGOs and distributors across the GCC, Africa and beyond depends on that being true for the vast majority of the UK formulary, every working day.

The exception exists because the same wholesale mechanisms that move stock efficiently to UK hospitals can also move it out of the country. When a specific medicine is genuinely short in national supply, whether because of a manufacturing interruption, a raw material problem, or an unexpected surge in demand, continued export of the limited remaining stock makes a UK shortage worse rather than better. To manage that risk, the Department of Health and Social Care maintains a mechanism for restricting the parallel export and stockpiling of individual medicines it judges to be at risk. It is a targeted, product-by-product tool, not a general export ban, and it is applied because of a domestic supply concern, not as a trade barrier against any particular overseas market.

The same mechanism is also used against hoarding, meaning UK wholesalers and pharmacies buying and holding more stock of a restricted line than their normal ordering pattern would justify. The underlying goal in both cases is the same: keep the available stock of a medicine that is genuinely short moving to the UK patients who need it, rather than sitting in a warehouse awaiting export or being held speculatively against future price movement.

The Legal Basis, in Plain Terms

A UK wholesale dealer does not export medicines under a general licence to trade freely in anything. Wholesale distribution of medicines in the UK operates under a Wholesale Dealer Authorisation, and every WDA carries conditions the licence holder must meet as a condition of keeping it. One of those conditions, when the government has restricted a specific product, is a straightforward obligation not to export that product without the required authorisation, and in some cases to notify the Department of Health and Social Care about stock levels of listed medicines.

Every WDA names a Responsible Person, and it is the Responsible Person who is accountable for making sure the licence holder actually meets that obligation in practice, not just on paper. That means checking the current restricted list before medicines are released for export, building the check into the day-to-day quoting and dispatch process rather than treating it as an occasional audit item, and being able to demonstrate, if asked by the MHRA, that the check happened and what the outcome was for a given order. For more on how this fits the broader compliance framework a WDA holder operates under, see our page on MHRA WDA and GDP compliance and our explainer on the UK WDA licence itself.

Getting this wrong is not a minor administrative slip. Exporting a restricted medicine without authorisation is a breach of licence conditions, and breaches of licence conditions are exactly the kind of finding that puts a wholesale dealer's authorisation, and with it its ability to trade at all, at risk. That is why a properly run UK exporter treats the check as non-negotiable rather than optional.

What This Means for an Overseas Buyer in Practice

From a buyer's seat, the restriction mechanism surfaces as a moment when a UK supplier declines to quote or supply a specific line that they would normally be able to source without difficulty. It is worth reframing what that moment actually tells you.

A legitimate UK supplier who says "we cannot supply this one at the moment, it is currently on the restricted export list" is showing you their compliance working, not their limitations. It means they checked, they know the current position, and they are not prepared to put their WDA at risk, or your consignment at risk of seizure or delay, by shipping something they should not. That is precisely the behaviour you want from a partner handling regulated pharmaceutical supply on your behalf.

The inverse is the real warning sign. A supplier who never declines a line, who will always say yes regardless of what is being asked for, is either not checking the current restriction position at all, or is sourcing through channels that sit outside normal UK wholesale controls. Either way, that is a supplier taking on regulatory risk that, in practice, gets passed straight through to you as the buyer, in the form of a consignment that can be held at export, a documentation trail that will not survive scrutiny, or a relationship with a supplier whose licence is not as secure as it looks.

Categories That Have Featured on Restriction Lists (and Why the List Changes)

It is tempting to ask for a definitive list of what is currently restricted, but publishing one here would be misleading by the time you read it, because the list is reviewed and updated as the underlying UK supply position for each medicine changes. What is useful instead is understanding the kind of product, and the kind of situation, that tends to attract a restriction.

At various points since this mechanism has been in active use, categories that have featured on UK export restriction lists include, illustratively: certain hormone replacement therapy products during periods of tight manufacturing supply, some ADHD medicines during shortages affecting several presentations at once, GLP-1 based diabetes and weight-management injectables during periods of exceptionally high demand, some emergency adrenaline auto-injector lines, and individual generic products within widely prescribed classes when a specific manufacturer's supply was interrupted. These are examples of the type of shortage-driven pattern that has led to restriction in the past, not a statement that any of these categories is restricted today.

Three things are consistent across every episode. The trigger is always a genuine or anticipated UK supply shortfall for that specific product, not a blanket policy against a therapeutic area. The restriction sits at the level of an individual presentation or strength rather than an entire drug class. And the list moves in both directions, with products added when a shortage risk is identified and removed once supply recovers, sometimes within a few months. Any buyer relying on last quarter's understanding of what is restricted is working from stale information. Verification has to happen at the point of enquiry, every time.

How the Restriction List Interacts with UK Medicine Shortages

The export restriction list rarely operates in isolation. It is one of a small set of tools the UK uses together to manage a genuine medicine shortage, and understanding how they connect helps explain why the restriction position on a given product can move quickly.

When a medicine shortage is identified nationally, the typical sequence runs roughly as follows. The manufacturer or the Department of Health and Social Care flags a supply problem affecting a specific product. If the shortfall is significant enough to risk UK patient access, the product may be added to the export restriction list, which keeps existing UK stock inside the country rather than allowing it to move out through parallel trade. In parallel, the Department of Health and Social Care and NHS England can issue a Serious Shortage Protocol for the same product, a separate mechanism that allows community pharmacists to supply a defined alternative, such as a different quantity, strength, or generic equivalent, without going back to the prescriber for a new prescription each time. The two tools address different points in the chain: the restriction manages where existing stock is allowed to go, and the protocol manages how the limited domestic stock is used once it is in the pharmacy.

As manufacturing recovers or an alternative source comes online, the shortage eases, and both the restriction and any associated protocol are typically withdrawn. The overseas buyer relevance is straightforward: if you are seeing a UK-licensed medicine restricted from export, there is usually a real UK shortage sitting behind it, which is worth knowing because the same underlying shortage may also be affecting the volumes an alternative UK supplier can offer, not just the one you first asked. For background on how UK hospitals themselves navigate shortage periods, see our guide on UK drug shortage supply.

What to Do When a Required Line Is Restricted

A restriction on a line you need is a genuine operational problem, not just a compliance footnote, so it is worth having a standard response ready rather than treating each occurrence as a surprise.

• Ask for written confirmation of the current position. Do not assume a product's restriction status from a previous order, and do not rely on a general list you have seen published elsewhere. Ask your supplier to confirm the position for that specific product, at that moment, and keep the confirmation on file.
• Consider a therapeutic alternative. Where clinically appropriate, and always in consultation with the prescribing clinician or your own pharmacy team, a different presentation, strength or an alternative product within the same therapeutic category may not carry the same restriction. Our hard-to-source medicines service exists for exactly this kind of substitution conversation.
• Build in a longer lead time. Restriction positions change as the underlying shortage resolves. If the clinical need allows some flexibility on timing, ask your supplier to flag when the position is likely to be reviewed rather than treating today's answer as final.
• Work with a supplier who checks before quoting, not after ordering. The costly version of this problem is finding out a line is restricted after documentation, payment terms and shipping have already been arranged. A supplier who checks at the enquiry stage saves that wasted cycle.
• Keep your own paper trail. For institutional, government and NGO buyers in particular, documenting that you sought the correct route and were told a line was restricted, rather than pursuing an unofficial channel, is often relevant to your own procurement governance and reporting.

How the Restriction Position Is Checked in Practice

Behind a simple "yes, we can supply that" or "no, that one is currently restricted" sits a repeatable internal process at a properly run UK wholesaler. When an enquiry comes in for a UK-licensed product intended for export, the product is cross-referenced against the current DHSC restricted export position before any quotation is issued. Because the list can move between the date of a quote and the date of dispatch, the check is repeated at despatch rather than treated as a one-off step completed weeks earlier.

The outcome of that check, and the date it was performed, is recorded in the order file. Where a product is restricted, the enquiry is declined for that line, and a compliant therapeutic alternative is proposed where one exists. This is the same discipline that sits behind any other document a UK wholesaler assembles for export, such as a Certificate of Pharmaceutical Product or a batch release certificate, described in our guide to UK pharmaceutical import documentation. A supplier that cannot describe this process when asked is one worth questioning before you rely on them for regulated supply.

How Euro Biom Handles Export Restrictions

Euro Biom is a UK MHRA-licensed pharmaceutical wholesale exporter, holding Wholesale Dealer Authorisation WDA(H) 59239, supplying UK-licensed, MHRA-authorised finished medicines to hospitals, Ministries of Health, NGOs and licensed distributors across the GCC, Africa, Turkey, the Levant and CIS/Asia. We are not a manufacturer, a pharmacy, or a regulatory consultancy, and this article is not intended as legal or regulatory advice for your organisation, it is intended to explain a mechanism that shapes what we are able to quote.

Before any UK-licensed line is quoted for export, we check its current position against the DHSC restricted export list. Where a product is restricted, we decline to quote or supply it, we document that position in the enquiry record, and, where a compliant alternative exists within the same therapeutic category, we propose it rather than leaving the enquiry unanswered. We repeat the check at despatch, not just at quotation, because the position can change between the two. This is standard practice for every enquiry we handle, not an exception applied only when something looks unusual, and it sits alongside the broader controls described on our supplier qualification and compliance pages.

We do not offer, and would never suggest, a way to work around a UK export restriction, and any supplier who does should be treated with real caution. If you would like us to check the current position on a specific line, or discuss a compliant alternative, our team responds to enquiries within one working day, and to urgent requests within four hours.